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ABSTRACT
Objective: The present study evaluated the influence of the duration of antiretroviral therapy on
insulin resistance among people living with HIV with lipodystrophic syndrome.
Methods: The study assessed 36 subjects of both sexes between 22 and 60 years old split into
three groups: 1) HIV-positive using antiretroviral with lipodystrophy syndrome (HIV+LIPO+); 2)
HIV-positive using antiretroviral therapy with no lipodystrophy syndrome (HIV+LIPO-); and 3)
HIV-negative and healthy (Control). The data were collected at the Special Unit for the Treatment
of Infectious Diseases (Unidade Especial de Tratamento para Doenças Infecciosas - UETDI) of the
Dyslipidemia Outpatient Clinic (Ambulatório de Dislipidemia - ADIS) of the General Hospital of the
Medical School of Ribeirão Preto (HC-FMRP). The biochemical assessment used laboratory kits
when the results were not available in the volunteer's records.
Results: Higher HOMA-IR values were observed for the group 1: HIV+LIPO+ (1,61 ± 1,17 )
compared to group 2: HIV+LIPO- (0,79 ± 0,87) and group 3: Control (0,46 ± 0,72 ) and such
values were positively correlated with the time of antiretroviral medication use (r=0,41).
Conclusions: The time of infection by HIV and the use of antiretrovirals impact the glucose
metabolism with changes in serum insulin levels and consequent insulin resistance and increased
risk for the development of diabetes and diseases related to carbohydrate metabolism.
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RESUMO
Objetivo: O presente estudo avaliou a influência do tempo de uso de antirretrovirais na resistên-
cia insulínica (HOMA-IR) entre pacientes vivendo com HIV, com síndrome lipodistrófica.
Artigo original
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INTRODUCTION
As previously described, HIV has tropism for
T-cells that express CD4 and macrophages, which
leads to a reduction in the number of lymphocyte
cells responsible for recognizing antigens foreign
to the organism. Drug therapy for those patients
began in 1987 with the use of Zidovudine (AZT)1.
In the mid-1990s, new drug classes such as pro-
tease and reverse transcriptase inhibitors have
become available2.
Those drugs significantly suppress viral rep-
lication and make HIV-positive patients have less
frequent clinical manifestations, which leads to a
substantial improvement in prognostic and qual-
ity of life of infected persons. That enabled a
change in the disease profile, which was cultur-
ally associated with death but that, as treatment
advanced, acquired a chronic character3,4.
Although this treatment improves the mor-
bidity rate and well-being of patients, its continu-
ous use may cause severe metabolic alterations
such as HIV-associated lipodystrophy (redistribu-
tion of body fat with peripheral lipoatrophy and
central lipohypertrophy) alone or accompanied by
hyperlipidemia, hyperglycemia, dyslipidemia, and
insulin resistance5,6.
Lipoatrophy is characterized by a decrease
in fat tissue in the face, particularly in the nasola-
bial folds, buttocks, and upper and lower limbs.
Lipohypertrophy, or lipomatosis, can occur in more
than one region simultaneously and corresponds
to the increase in central abdominal fat tissue and
in the cervical back, gynecomastia, and enlarged
breasts among women. The etiology of lipodys-
trophy in treated HIV infection is multifactorial7,8,9.
Insulin resistance is defined as a subnor-
mal biological response to a given concentration
of this hormone. Systemic inflammation associated
with HIV infection might promote monocyte migra-
tion across the vascular endothelium, leading to
an increased number of activated macrophages
in fat. Cytokines and viral proteins can inhibit
adipocyte differentiation as well as induce mito-
chondrial dysfunction and insulin resistance10.
Those disorders cause alterations in the
patients’ glucose metabolism and may pose sig-
nificant cardiovascular risk. Moreover, studies have
shown a reduction in the quality of life of patients
due to lipodystrophy-associated body changes,
which limits adherence to treatment. Better un-
derstanding the relation between lipodystrophy
syndrome among HIV-positive patients and insu-
lin resistance is of key importance to provide bet-
ter quality of life to those persons.
With that in mind, the present study as-
sessed whether HIV-positive patients with and
without lipodystrophy syndrome in antiretroviral
therapy had insulin resistance and the influence
of the duration of antiretroviral use.
Métodos: Foram avaliados 36 indivíduos de ambos os sexos, com idade entre 22 e 60 anos,
divididos em três grupos: 1) Soropositivo para HIV em uso de TARV com síndrome de lipodistrofia
(VIH + LIPO +); 2) Soropositivo para HIV em uso de TARV sem síndrome de lipodistrofia (VIH +
LIPO-); 3) Soronegativo para HIV (Controle). Os dados foram coletados na Unidade Especial de
Tratamento para Doenças Infecciosas (UETDI), no Ambulatório de Dislipidemia (ADIS) do Hospital
das Clínicas da Faculdade de Medicina de Ribeirão Preto (HC-FMRP). Para a análise bioquímica
foram utilizados kits de laboratório, quando os mesmos não estavam disponíveis nos prontuário
eletrônico.
Resultados: Foram observados maiores valores de HOMA-IR para o grupo GRUPO 1: HIV+LIPO+
(1,61 ± 1,17), comparado aos grupos GRUPO 2: HIV+LIPO- (0,79 ± 0,87) e GRUPO 3: Controle
(0,46 ± 0,72), sendo que o HOMA-IR apresentou correlação positiva com o tempo de uso dos
antirretrovirais (r=0,41).
Conclusão: O tempo de infecção por HIV e o uso de antirretrovirais influenciam o metabolismo
glicídico, com modificações nos níveis séricos de insulina e consequentemente resistência à insu-
lina e maior risco para desenvolver diabetes e enfermidades relacionadas ao metabolismo de
carboidratos.
Palavras chave: HIV. Lipodistrofia. Resistência à Insulina. Terapia Antirretroviral.
Medicina (Ribeirão Preto, Online.) 2018;51(4):265-70 267
Influence of the duration of antiretroviral use on insulin resistance.
MATERIALS AND METHODS
Site
The present descriptive, analytical, cross-
sectional study was carried out at the Clinics Hos-
pital of the Medical School of Ribeirão Preto (HC/
FMRP) and was analyzed and approved by the
Committee of Research Ethics of the hospital and
the Medical School of Ribeirão Preto (HCRP proc-
ess no. 3900/2011).
Participants were recruited at the Special
Unit for the Treatment of Infectious Diseases
(Unidade Especial de Tratamento para Doenças
Infecciosas – UETDI) of the Nutrition and Infec-
tious Diseases Outpatient Clinic of the Clinics
Hospital of the Medical School of Ribeirão Preto
(HC-FMRP). For the control group, individuals were
selected from different specialties of the Clinics
Hospital who were found to be HIV-negative in a
test performed for reasons other than the re-
search while following the inclusion and exclusion
criteria of the study.
Study Group
The study assessed 36 subjects of both
sexes between 22 and 60 years old split into three
groups:
1. Seropositive for HIV using ART with lipodystro-
phy syndrome (HIV+LIPO+);
2. Seropositive for HIV using ART with no lipodys-
trophy syndrome (HIV+LIPO-);
3. Seronegative for HIV and healthy (Control).
In order to be included in the HIV+LIPO+
group, the individual had to report loss and/or
accumulation of fat in specific regions of the body,
which was confirmed through a clinical examina-
tion according to the criteria by Sutinen J. and
Yki-Järvinen H.11.
Therefore, it was essential that at least one
site showed lipoatrophy, i.e., visible loss of fat in
peripheral regions (arms or legs) or face accom-
panied or not by lipohypertrophy, i.e., accumula-
tion of fat in the abdominal region, dorsal gibbos-
ity, or gynecomastia12.
Anthropometric Evaluation
Weight and height were measured accord-
ing to Frisancho (1989). The body mass index (BMI)
was calculated from the relation between the in-
dividual’s weight (kg) divided by the square of the
height (m). Thus, the unit of measurement of the
BMI is kg/m2.
Biochemical Evaluation
The laboratory analyses of the biological
material collected were performed at the Multi-
User Laboratory of Nutrition and Metabolism of
the Medical School of Ribeirão Preto using blood
collected in the morning in 5 mL BD Vacutainer®
SST® II Advance® tubes after 12 h of fasting.
After collection, the blood samples were cen-
trifuged in a Universal 320R Hettich® centrifuge
for 10 min at 23°C and 3,500 rpm. The sera ob-
tained were stored at -20°C until the analyses.
The biochemical tests performed in the
present study aimed to assess glucose metabo-
lism in the subjects. Fasting glycemia was deter-
mined by the colorimetric method using Labtest®
(Labtest Diagnóstico S. S., Lagoa Santa, Minas
Gerais, Brazil) kits and a Molecular Devices®
Spectro Max M5 device, while fasting insulinemia
was determined by a commercial kit using solid-
phase chemiluminescence immunometric assay
(IMMULITE®, DPC, Los Angeles, California, USA).
Calculating HOMA (Homeostatic Model
Assessment)
HOMA was calculated from the serum con-
centrations of glucose and insulin, which assessed
insulin resistance. According to the guidelines of
the Brazilian Diabetes Society, an insulin resist-
ance diagnostic requires HOMA-IR > 4.65. HOMA
is calculated using the formula: fasting glycemia
(mmol/L = mg/dL ÷ 18) × fasting insulinemia (µU/
mL)/22.5.
RESULTS
The 36 participants of the present study, 12
females and 24 males, were assigned to one of
the three groups, with 12 participants in each
group. The nutritional status assessment showed
that all groups had average BMI below 24.9 kg/
m2, i.e., within the limits to be classified as eu-
trophic.
The HIV+LIPO+ group had the highest mean
age (46.7±8.9 years). It also had the longest time
of HIV infection, time under antiretroviral therapy,
and highest CD4+ cell count, with a difference
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(p<0.05) in the first two variables compared to
group HIV+LIPO-.
All data presented above can be found in
Table 1.
So that the biochemical profile of the groups
in the present study could be known, the results
of the biochemical analyses were represented as
means and standard deviation for each group. An
analysis of glycemic control markers shows a dif-
ference between groups HIV+LIPO+ and Control
for the values of insulin and HOMA-IR (p<0.05),
with the former having higher means (Table 2).
DISCUSSION
The present study investigated possible
alterations in glucose metabolism by HIV infec-
tion, time of antiretroviral therapy, and presence
or absence of lipodystrophy syndrome.
The groups of individuals infected with HIV
were mostly male, in accordance with the statisti-
cal data of the Brazilian Ministry of Health of cases
of HIV registered in the Information System on
Diseases of Compulsory Declaration (Sistema de
Informação de Agravos de Notificação – Sinan)
between 2007 and 2015, which informs 61,904
cases among men and 31,331 among women 1.
This study showed an association of longer
antiretroviral therapy use with increased devel-
opment of l ipodystrophy syndrome in the
HIV+LIPO+ group. The extended use of ART is,
therefore, related to a number of complications
and metabolic disorders, including redistribution
of body fat and lipodystrophy13,14.That shows the
importance of continuously monitoring patients
under antiretroviral therapy so that drug asso-
ciation can be adequated or even switched to
other antiretroviral medications.
Table 1
Characteristics related to age group, anthropometric data, and HIV infection in the different groups of the
study.
HIV+LIPO+ HIV+LIPO- CONTROL
Variables Fem(n=3)/Male(n=9) Fem(n=2)/Male(n=10) Fem(n=7)/Male(n=5)
(Mean±SD) (Mean±SD) (Mean±SD)
Age (years) 46.7±8.9 37.9±9.0 30.6±9.4
Weight (kg) 72.69±11.5 72.85±17.66 67.17±13.48
Height (m) 1.71±0.06 1.72±0.1 1.68±0.06
BMI (kg/m2) 24.83±3.27 24.42±3.89 23.88±4.22
Time with HIV (years) 14±5.46 5.92±6.17 -
Time in antiretroviral therapy (years) 11.25±3.57 4.32±3.24 -
CD4+ (cells/mm3) 561.67±257.25 539.83±239.66 -
Viral load (copies/mL) Undetected Undetected -
Note: Kruskal-Wallis test. The values are expressed as means±standard deviation. Abbreviations: BMI = body mass index;
          Undetected viral load: <50 copies/mL.
Table 2
Biochemical profile of the groups studied represented by means and standard deviation.
TESTS HIV+LIPO+ HIV+LIPO- CONTROL
(Mean±SD) (Mean±SD) (Mean±SD)
Glycemia (mg/dL) 102.27±30.03 96.41±16.05 84.12±6.07
Insulin (µU/mL) 6±3.69* 3.3±3.36 2.09±3.28*
HOMA-IR 1.61±1.17* 0.79±0.87 0.46±0.72*
Note: Kruskal-Wallis test. The values are expressed as means±standard deviation. The presence of an * represents p<0.05.
          Abbreviations: HOMA-IR: homeostasis model assessment – insulin resistance
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HOMA-IR was statistically significant when
the HIV+LIPO+ group was compared with the Con-
trol group (Table 2), which was expected given
that insulin resistance is an important complica-
tion associated with lipodystrophy. Insulin resist-
ance was not significantly different when the
HIV+LIPO- group was compared with the
HIV+LIPO+ and Control groups. Our results sup-
port previous investigation by Deminice R. et al.
(2013), which showed significant differences only
between the control group and HIV+LIPO+15.
Even though significant differences in insu-
lin resistance were not found in other groups of
this study, the glucose metabolism of all HIV-posi-
tive patients must be controlled in order to pre-
vent lipodystrophy and its complications. In addi-
tion to the constant monitoring of the HIV patient,
early lifestyle adjustments are necessary, such as
in diet and physical activity.
It can be seen that the presence of insulin
resistance has a positive correlation with
antiretroviral therapy initiation (Table 3). Such
association matches the literature, where it is
reported by 8-10% of the patients with HIV, an
alteration in glucose metabolism seen as early as
a few months after drug therapy is initiated16,17,18.
Also using HOMA-IR values, another study
found statistical differences among patients un-
der antiretroviral therapy, with higher glycemia
levels, larger area under the curve of glycemia
variation, and higher values of fasting insulinemia
and HOMA-IR compared with patients not in
antiretroviral therapy19.
The adherence of HIV-positive patients to
antiretroviral therapy leads to improvements in
clinical results, may control the advance of the
disease, and, thus, tends to lower the mortality
rate. That would result in longer life expectancy
since the quality of life of the patients improves.
Nonetheless, the use of antiretroviral
therapy may be accompanied by several impacts
on health, potentializing some metabolic syn-
dromes such as systemic arterial hypertension,
causing increased risk of the development of car-
diovascular diseases, besides abnormal body fat
distribution.
Insulin resistance is also shown to increase,
whose effects range from alterations in glucose
metabolism to the development of type-2 diabe-
tes mellitus, as reported in the literature8,20.
In face of the positive relation between the
time using antiretroviral therapy and time with HIV
and changes in glucose metabolism, evidence
suggests that, despite the improvement in life
expectancy, those alterations are persistent and
require care during treatment.
 There are limiting aspects of this study to
be signaled. Besides antiretroviral therapy dura-
tion, the duration of infection by HIV is also posi-
tively related to changes in glucose metabolism.
Another limitation is the sensitivity of the resist-
ance marker to HOMA. In addition, volunteers di-
agnosed with pre-diabetes and type-2 diabetes
according to parameters by the Brazilian Diabe-
tes Society 21 were not excluded from the study
groups.
CONCLUSION
The time of HIV infection, the time using
antiretroviral therapy, and the presence or ab-
sence of lipodystrophy negatively impact glucose
metabolism and lead to an increase in peripheral
insulin resistance, glycemia, and plasma insulin
levels.
Such increase is even more pronounced in
HIV-positive individuals using antiretroviral
therapy and showing lipodystrophy, while HIV-
positive individuals under antiretroviral therapy
with no lipodystrophy also show this increase, but
more mildly and with no statistical significance for
the group of infected patients.
Table 3
Pearson correlation for HIV-positive patients regard-





Time with HIV (years) 0.83*
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